Community Trust ScoreVerified
Cypherpunk Technologies is making a hard pivot. The Winklevoss-backed company, sitting on a massive Zcash treasury, just posted a $37.8 million loss for the first half of 2026 — and it’s now betting part of its future on a cancer drug that already stumbled in Phase 2.
The numbers are pretty rough. Cypherpunk holds 323,394 ZEC, which works out to roughly $157 million in crypto assets. But the company’s market cap on Nasdaq sits at just $74 million. That gap gives it a multiple-to-Net Asset Value ratio of 0.47x — meaning the market values the company at less than half what its Zcash alone is worth. Even factoring in pre-funded warrants, that ratio only climbs to 0.96x, still below the actual ZEC value. It’s the kind of discount that raises real questions about investor confidence, and it’s been building for a while.
The stock tells its own story.
Shares Down 96% Over Five Years
Cypherpunk shares peaked at $3.70 last November. They’ve since collapsed to below $0.69. That’s a 96% drop over five years — brutal by any measure. The company keeps saying it plans to maintain operations, but with only $7.6 million in cash and cash equivalents as of June 30, the runway isn’t long. Operating losses are ongoing. The cash cushion is thin. And the FDA trials it wants to run aren’t cheap.
The crypto side of the business isn’t exactly firing either. Zcash has been basically flat over the year, so Cypherpunk can’t count on ZEC appreciation to bail it out. The company originally built its identity around rapidly accumulating Zcash — the privacy-focused cryptocurrency — and it still holds 1.92% of the circulating supply. The stated goal is to eventually reach at least 5%. That target looks distant right now, and the financial pressure makes it harder to get there.
And there’s the Gemini connection. Cameron and Tyler Winklevoss control Gemini, the exchange that serves as custodian for Cypherpunk’s Zcash holdings. So the twins are woven into both the crypto asset side and the broader governance of the company. Whether that relationship helps unlock funding options or just deepens the entanglement isn’t totally clear yet.
Sirexatamab’s Rocky Path to Phase 3
The cancer drug push centers on Sirexatamab, an anti-DKK1 antibody. It didn’t outperform the control group in its Phase 2 study — specifically, it failed to show a meaningful advantage in progression-free survival. Not great. But the FDA granted it fast track status anyway, which speeds up the regulatory review process and gives the company some room to maneuver. Cypherpunk is now planning a Phase 3 trial targeting colorectal cancer, involving roughly 270 patients.
That trial costs money Cypherpunk doesn’t obviously have sitting around. The company is weighing its options — either funding the Phase 3 independently through some kind of spin-out structure, or finding a partner willing to co-develop Sirexatamab. No deal has been announced. No partner has been named. The source didn’t specify a timeline for that decision, and it’s probably not imminent.
The Phase 2 miss is the awkward fact hanging over all of this. Drug development is brutal even when Phase 2 works. When it doesn’t, raising money for Phase 3 gets significantly harder. Cypherpunk seems to believe the FDA’s fast track designation compensates for some of that, and maybe it does — regulators don’t hand that designation out carelessly. But it’s not a guarantee of anything, and investors have clearly priced in the uncertainty.
So the company is essentially running two capital-intensive strategies at once. It wants to keep accumulating Zcash toward that 5% target. And it wants to fund a major clinical trial for a drug that already had a setback. With $7.6 million in cash, doing both seems like a stretch.
What the Funding Gap Actually Means
The accumulated deficit situation is serious. Cypherpunk is actively looking for external capital — potential collaborations on the pharma side, possibly other structures. But the company hasn’t locked anything down, and the market valuation discount makes equity raises painful. Selling ZEC to fund operations would chip away at the very asset base the company’s crypto thesis depends on.
It’s a genuinely awkward spot. The Zcash holdings are real and substantial. The FDA fast track is real. But the cash position is tight, the stock is near multi-year lows, and the drug’s Phase 2 results weren’t the kind that make institutional investors rush to write checks.
Cypherpunk holds 1.92% of Zcash’s circulating supply — still well short of the 5% target it set for itself.
Frequently Asked Questions
How much Zcash does Cypherpunk Technologies hold?
Cypherpunk holds 323,394 ZEC, representing 1.92% of the circulating supply, with a value of approximately $157 million — well above the company’s $74 million Nasdaq market cap.
What happened to Cypherpunk’s cancer drug in clinical trials?
Sirexatamab, Cypherpunk’s anti-DKK1 antibody, failed to outperform the control group in its Phase 2 study but received FDA fast track status; the company is planning a Phase 3 colorectal cancer trial with roughly 270 patients.
